Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

As steep patent cliff looms, Shionogi moves to develop own U.S. sales staff

For much of the company’s 141-year history, Japan’s Shionogi & Co. Ltd. has played safe when selling drugs in the United States and other overseas markets – relying on bigger partners to promote products and avoiding the cost of maintaining a large sales force.

Read More »

Novartis wins Gilenya reprieve as judge blocks generics

Novartis won a U.S. federal court order preventing rival generic makers from selling versions of the Swiss drugmaker’s top-selling multiple sclerosis medicine Gilenya in the United States, at least until a patent dispute is resolved.

Read More »

Sanofi bets on new CEO to drive sluggish drug sales

In veteran drug salesman Paul Hudson, Sanofi’s 100,000-plus employees are getting a new chief executive who relishes a good commercial fight.

Read More »

Sanofi loses German patent case against Amgen over cholesterol drug

Germany’s highest civil court rejected French drugmaker Sanofi’s bid to fend off a legal challenge by U.S. rival Amgen against Sanofi’s cholesterol drug Praluent.

Read More »

British Columbia to be first Canadian province to switch patients to biosimilars

The Canadian province of British Columbia said its public drug plan will switch as many as 20,400 patients from three branded biologic drugs to cheap near-copies called biosimilars.

Read More »

UK’s Vectura wins patent infringement case against GlaxoSmithKline in U.S.

British drugmaker Vectura Group Plc won a patent infringement litigation case against GlaxoSmithKline Plc in the United States and was awarded $89.7 million in damages for the period from August 2016 through December 2018.

Read More »

Novo Nordisk Q1 2019 profit tops forecast

Danish drugmaker Novo Nordisk beat first-quarter 2019 operating profit forecasts, helped by higher sales of the company’s biggest new drug hope, a treatment for type 2 diabetes.

Read More »

AbbVie’s Skyrizi drug to treat psoriasis wins U.S. approval

The U.S. FDA approved AbbVie Inc.’s Skyrizi as a treatment for plaque psoriasis at a time when the company’s blockbuster psoriasis medicine Humira faces patent pressures.

Read More »

U.S. Supreme Court rejects Allergan bid to use tribe to shield drug patents

The U.S. Supreme Court cast aside pharmaceutical company Allergan Plc’s unorthodox bid to shield patents from a federal administrative court’s review by transferring them to a Native American tribe.

Read More »

Gilead Sciences Cuts 150 Sales Jobs

The loss of patent protection on two drugs is forcing Gilead Sciences to terminate about 20 percent of the company’s sales team, according to reports.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom